CG Oncology Inc
CGON
NASDAQ
Biotechnology
$75.03
USD
+0.32 (+0.43%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.79B
Volume 596.3K
Revenue
$5.07M
TTM
+666.0%
YoY
Gross Margin
-50%
TTM
-150.0%
YoY
Net Income
$-186.75M
TTM
-76.9%
YoY
Operating Cash Flow
$-160.01M
TTM
-95.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.1 | 0.0 | 1.7 | 2.3 | 1.1 |
YoY Growth | -90.2% | -100.0% | +3774.4% | +409.2% | +1982.7% |
Cost of Revenue | 0.0 | 0.0 | 1.6 | 3.1 | 3.0 |
Gross Profit | 0.1 | 0.0 | 0.1 | -0.7 | -1.9 |
Selling, General & Administrative | 14.8 | 17.4 | 23.3 | 18.0 | 20.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 42.3 | 48.7 | 51.2 | 48.0 | 64.5 |
Operating Income | -42.2 | -48.7 | -51.1 | -48.7 | -66.4 |
EBITDA | -42.2 | -48.6 | -50.7 | -47.9 | -65.5 |
Other Income / Expense | 0.0 | -0.0 | -0.1 | -0.1 | -0.1 |
Total Other Income / Expense | 7.8 | 7.3 | 7.3 | 7.4 | 6.2 |
Income Before Income Taxes | -34.5 | -41.4 | -43.8 | -41.3 | -60.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -34.5 | -41.4 | -43.8 | -41.3 | -60.2 |
Consolidated Net Income / Loss | -34.5 | -41.4 | -43.8 | -41.3 | -60.2 |
Net Income Attributable to Common Shareholders | -34.5 | -41.4 | -43.8 | -41.3 | -60.2 |
Basic EPS | -$0.45 | -$0.54 | -$0.57 | -$0.52 | -$0.71 |
Diluted EPS | -$0.45 | -$0.54 | -$0.57 | -$0.52 | -$0.71 |
Basic Shares Outstanding | 76.2M | 76.2M | 76.7M | 80.1M | 84.5M |
Diluted Shares Outstanding | 76.2M | 76.2M | 76.7M | 80.1M | 84.5M |